Literature DB >> 20232773

Nonsteroidal anti-inflammatory drug hypersensitivity syndrome: a multicenter study. II. Basophil activation by nonsteroidal anti-inflammatory drugs and its impact on pathogenesis.

A L De Weck1, M L Sanz, P M Gamboa, J M Jermann, M Kowalski, W Medrala, J Sainte-Laudy, M S Schneider, J M Weber, A Wolanczyk-Medrala.   

Abstract

BACKGROUND: Patients who are clinically hypersensitive to nonsteroidal anti-inflammatory drugs (NSAIDs) sometimes present basophil activation in vitro, and in 50% of cases a parallel response to release of sulfidoleukotrienes (cellular allergen stimulation test) is observed. These phenomena occur not only in clinically hypersensitive patients, but also in some healthy controls who tolerate NSAIDs.
MATERIAL AND METHODS: We studied 16 clinically hypersensitive patients, 22 controls tolerating NSAIDs, and 29 healthy blood donors (clinical NSAID status unknown) using 2 different basophil isolation techniques (buffy coat or plasma leukocytes).
RESULTS: In a population of 13 aspirin-tolerant healthy controls and 29 healthy blood donors, basophil activation with aspirin, diclofenac, and naproxen was analyzed at 4 different concentrations. The results in the 2 groups were quite similar in qualitative terms. Choosing a cutoff of 5% and a stimulation index >2, the proportion of positive results increased with the concentration. There were more positive results at all concentrations using the plasma leukocyte technique.
CONCLUSIONS: The most important finding of this study is that basophil activation by NSAIDs occurs not only in clinically hypersensitive patients but also, to a very variable extent and on an individual basis, in apparently normal healthy individuals who tolerate NSAIDs. The phenomenon is clearly dose-related, and hypersensitive patients seem to react to lower NSAID concentrations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232773

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  8 in total

1.  [Cellular in-vitro assays. Applicability in daily routine].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2010-11       Impact factor: 0.751

2.  Development of a genetic marker set to diagnose aspirin-exacerbated respiratory disease in a genome-wide association study.

Authors:  H S Chang; S W Shin; T H Lee; D J Bae; J S Park; Y H Kim; S T Uh; B W Choi; M K Kim; I S Choi; B L Park; H D Shin; C S Park
Journal:  Pharmacogenomics J       Date:  2015-02-24       Impact factor: 3.550

Review 3.  BAT in the Diagnosis of Drug Allergy: a Novel Tool in Clinical Daily Practice?

Authors:  Lucila Campos; Violeta Régnier Galvão; Jorge Kalil; Mariana Castells; Pedro Giavina-Bianchi
Journal:  Curr Allergy Asthma Rep       Date:  2019-03-11       Impact factor: 4.806

4.  Pathogenic Mechanisms and In Vitro Diagnosis of AERD.

Authors:  Dirk Schäfer; Steffen Maune
Journal:  J Allergy (Cairo)       Date:  2012-05-10

5.  Elevation of Eosinophil-Derived Neurotoxin in Plasma of the Subjects with Aspirin-Exacerbated Respiratory Disease: A Possible Peripheral Blood Protein Biomarker.

Authors:  Seung-Woo Shin; Jong Sook Park; Choon-Sik Park
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

6.  Diagnostic value of clinical parameters in the prediction of aspirin-exacerbated respiratory disease in asthma.

Authors:  Hun Soo Chang; Jong-Sook Park; An-Soo Jang; Sung-Woo Park; Soo-Taek Uh; Young Hoon Kim; Choon-Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2011-07-01       Impact factor: 5.764

7.  Comparison of CD63 Upregulation Induced by NSAIDs on Basophils and Monocytes in Patients with NSAID Hypersensitivity.

Authors:  N Abuaf; H Rostane; J Barbara; C Toly-Ndour; H Gaouar; P Mathelier-Fusade; F Leynadier; C Francès; R Girot
Journal:  J Allergy (Cairo)       Date:  2011-12-01

8.  Threshold for positivity and optimal dipyrone concentration in flow cytometry-assisted basophil activation test.

Authors:  Natalia Hagau; Dan Longrois; Cristina Petrisor
Journal:  Allergy Asthma Immunol Res       Date:  2013-08-07       Impact factor: 5.764

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.